Mauna KEA Technologies: insider trades · France · AMF

About Mauna KEA Technologies

Mauna Kea Technologies is a French listed medical technology company specialized in in vivo cellular imaging for endoscopy. Founded in 2000 by Sacha Loiseau, a physicist and former NASA Jet Propulsion Laboratory astrophysicist, the company built its identity around Cellvizio®, a proprietary confocal laser endomicroscopy (CLE) platform that enables physicians to visualize cells in real time at very high magnification during endoscopic procedures. The core value proposition is to provide immediate histology-like information at the point of care, helping clinicians improve diagnosis, guide treatment decisions, and make better procedural choices. The company is headquartered in France and operates in a highly international environment, with commercial, regulatory, and clinical activities spanning the United States, Europe, and selected partner markets in Asia. Mauna Kea Technologies’ business model is centered on the design, commercialization, and ongoing development of the Cellvizio platform, together with its miniature probes and related software. The company serves several medical specialties, notably gastroenterology, pulmonology, urology, and emerging applications in oncology, immunology, and image-guided surgery. Its market position is that of a highly specialized, technology-driven niche player and one of the historical pioneers in endomicroscopy. Management highlights more than 1,100 peer-reviewed publications supporting the technology, along with deployment in hundreds of medical institutions worldwide, which helps underpin the platform’s clinical credibility and scientific recognition. From an industrial strategy standpoint, Mauna Kea Technologies has recently updated its Cellvizio platform and is working to broaden clinical adoption through artificial intelligence, easier workflow integration, and new commercial partnerships. The most recent financial disclosures point to a turnaround phase after a period of revenue pressure and balance-sheet strain. In 2025, the company completed a comprehensive debt restructuring and strengthened equity, while core sales showed a sequential acceleration through the year, supported by the U.S. market and by solutions such as CellTolerance®. In the first quarter of 2026, management reported strong core sales growth and noted additional regulatory momentum, including CE marking under the EU Medical Device Regulation, together with new international expansion opportunities. For investors, Mauna Kea Technologies therefore combines a differentiated medical imaging technology, specialized market exposure, and a still-material financial risk profile, although recent operating trends have become more encouraging in 2026.